A Phase 2 interventional study of ABX464 50mg and Matching Placebo in Rheumatoid Arthritis, sponsored by Abivax S.A.. Completed at 24 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-15.
Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 164th largest by enrollment of the 222 interventional ones that give a count, is one of 19 that started in 2019, is one of 33 in phase 2, and was the 230th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
University Hospital, Tours · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, Argentina, Brazil and 6 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
357 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 37 · Phase 3 75 · Phase 4 37
First in 2000; this study’s year is marked. 19 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 167 across the 222 interventional studies, 271 across the 134 observational. Of the 261 that completed or were terminated, 99 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
174 of 357 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 2 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
| NCT04870203Phase 3University Hospital, BordeauxCombination of Baricitinib and Anti-TNF in Rheumatoid Arthritis | 2027-03 |
| NCT07321340Centre Hospitalier Universitaire de Saint EtienneInsole Optimization for Rheumatoid Arthritis Patients | 2026-11 |
| NCT06235645University Hospital, ToursdEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound | 2026-11 |
| NCT04292067Assistance Publique - Hôpitaux de ParisCharacterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis | 2026-11 |
Add all 16 to your calendar (.ics) → With an account.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one or more anti- tumor necrosis factor alpha (TNFα) therapies.
This is a randomized, double-blind, placebo-controlled, multicenter study. The study will consist of 3 phases: a screening phase, a treatment phase, and a follow-up phase.
Approximately 60 participants with active Rheumatoid Arthritis will be randomly assigned to receive placebo, 50mg ABX464 or 100mg ABX464 during the treatment phase.
The maximum period of active treatment will be 12 weeks. The maximum duration of study participation will be 17 weeks.
Participant safety will be monitored throughout the study. In addition, several experimental and clinical endpoints will be assessed to obtain information on preliminary efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks + methotrexate
Drug: ABX464 50mg · Drug: Matching Placebo · Drug: Methotrexate
Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks + methotrexate
Drug: ABX464 100mg · Drug: Methotrexate
Participants will receive two capsules of matching placebo once daily for 12 weeks + methotrexate
Drug: Matching Placebo · Drug: Methotrexate
ABX464 is a new anti-inflammatory drug
Also known as: obefazimod 50mg
placebo matching with ABX464
Also known as: Placebo
ABX464 is a new anti-inflammatory drug
Also known as: obefazimod 100mg
MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
Also known as: MTX
Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo
TEAE definition is undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment
Time frame: through study completion, an average of 15 weeks
Number of Patients Achieving ACR20 Response
The categorical American College of Rheumatology 20% (ACR20) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% improvement in the ACR response.
Time frame: at Week 12
Number of Patients Achieving ACR20/50/70 Response
Number of patients who achieved at least 20%, 50% or 70% improvement in the American College of Rheumatology (ACR) response.
Time frame: Week 12
Change From Baseline in C-reactive Protein (CRP)
Change from baseline in C-reactive protein (CRP) at Week 12
Time frame: Week 12
Number of Patients Achieving DAS28-CRP Response
Number of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) \[DAS28-CRP\] response will be measured as moderate/good European League Against Rheumatism (EULAR) response
Time frame: Week 12
Change From Baseline in Disease Activity Scores (DAS-CRP) (28 Joints) [DAS28]
The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (CRP ), and patient's global assessment of disease activity (PtGA). DAS28-CRP = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.36 Ln \[CRP(mg/L)+1\] + 0.014 PtGA(VAS100mm) + 0.96 Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
Time frame: Week 12
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Change from baseline in erythrocyte sedimentation rate (ESR) at Week 12
Time frame: Week 12
Number of Patients Achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) [DAS28-ESR] Remission
Number of patients achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) \[DAS28-ESR\]remission, which is defined as DAS2-ESR \< 2.6
Time frame: Week 12
Change From Baseline in Disease Activtiy Score (DAS)28-Erythrocyte Sedimentation Rate (ESR)
The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (ESR), and patient's global assessment of disease activity (PtGA). DAS28-ESR = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.70 Ln \[ESR(mm/h)\] + 0.014 PtGA(VAS100mm) Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. change from baseline at weeks 12: the bigger negative score shows a bigger improvment
Time frame: 12 weeks
Change From Baseline in Simplified Disease Activity Index Score (SDAI)
SDAI is a validated index of rheumatoid arthritis disease activity. The SDAI calculation is based on 28 tender and swollen joint counts, C-Reactive Protein (CRP), patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). SDAI score= tender28 + swollen28 + CRP + (PtGA/10) + (PrGA/10). A moderate activity is defined by a SDAI score \>11 to 26 included. A high activity is defined by a SDAI score \>26. Change from Baseline: the higher negative number shows a bigger improvment
Time frame: Week 12
Change From Baseline in Clinical Disease Activity Index Score (CDAI)
CDAI is a validated index of rheumatoid arthritis disease activity. The CDAI calculation is based on 28 tender and swollen joint counts, patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). CDAI score= tender28 + swollen28 + (PtGA/10) + (PrGA/10). A moderate activity is defined by a CDAI score \>10 to 22 included. A high activity is defined by a CDAI score \>22. Change from Baseline: the higher negative number shows a bigger improvment
Time frame: Week 12
Number of Patients Achieving Low Disease Activity (LDA)
Number of patients achieving a Low Disease Activity (LDA) which is defined as DAS28-ESR \<=3.2
Time frame: Week 12
Number of Patients Achieving Simplified Disease Activity Score (SDAI) Remission
Number of patients achieving Simplified Disease Activity Score (SDAI) remission, which is considered achieved if the SDAI score ≤ 3.3
Time frame: Week 12
Number of Patients Achieving Clinical Disease Activity (CDAI) Remission
Number of patients achieving Clinical Disease Activity (CDAI) remission, which is considered achieved if the CDAI score ≤ 2.8
Time frame: Week 12
Number of Patients Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission
The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1
Time frame: Week 12
Change From Baseline in Tender/Painful Joint Count (TJC28)
Change from Baseline in Tender/painful joint count based on 28-joint assessment (TJC28) at Week 12 TJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is
Time frame: 12 weeks
Change From Baseline in Swollen Joint Count (SJC)
Change from Baseline in Swollen joint count based on 28-joint assessment (SJC28) at Week 12 SJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is
Time frame: 12 weeks
Change From Baseline in Pain Visual Analog Scale
Change from Baseline in Pain Visual Analog Scale (Pain-VAS) at week 12 The VAS range from 0 to 10 cm (the higher, the more painful) A bigger negative change from baseline shows a bigger improvment
Time frame: 12 weeks
Change From Baseline in Patient Global Assessment of Disease (PtGA)
Change from Baseline in Patient Global Assessment of Disease (PtGA) . This is a patient's self assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: a bigger negative number shows a bigger improvment
Time frame: 12 weeks
Change From Baseline in Investigator Global Assessment of Disease (PrGA)
Change from Baseline in Investigator global assessment of disease (PrGA): investigator's assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: the higher negative number shows a better improvement
Time frame: 12 weeks
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
Change from Baseline in Health Assessment questionnaire disability index (HAQ-DI) at Week 12 There are 8 sections in this questionnaire: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section, i.e. if one question is scored 1 and another 2, then the score for the section is 2. In addition, if an aide or device is used or if help is required from another individual, then the minimum score for that section is 2. The 8 scores of the 8 sections are summed and divided by the number of section answered. This gives a score range from 0 to 3 (the bigger the worst activity). The change from Baseline: the bigger negative number shows a bigger improvment
Time frame: 12 weeks
| Milestone | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Started | 21 | 19 | 20 |
| Completed | 18 | 6 | 19 |
| Not completed | 3 | 13 | 1 |
TEAE definition is undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo | 18 | 18 | 14 |
The categorical American College of Rheumatology 20% (ACR20) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% improvement in the ACR response.
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Patients Achieving ACR20 Response | 9 | 3 | 4 |
Number of patients who achieved at least 20%, 50% or 70% improvement in the American College of Rheumatology (ACR) response.
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| ACR20 response | 9 | 3 | 4 |
| ACR50 response | 5 | 2 | 1 |
| ACR70 response | 4 | 1 | 1 |
Change from baseline in C-reactive protein (CRP) at Week 12
| mg/L | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in C-reactive Protein (CRP) | -4.31 ± 28.83 | 0.62 ± 4.89 | -0.65 ± 18.74 |
Number of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) \[DAS28-CRP\] response will be measured as moderate/good European League Against Rheumatism (EULAR) response
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Patients Achieving DAS28-CRP Response | 14 | 6 | 8 |
The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (CRP ), and patient's global assessment of disease activity (PtGA). DAS28-CRP = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.36 Ln \[CRP(mg/L)+1\] + 0.014 PtGA(VAS100mm) + 0.96 Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
| score on a scale | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Disease Activity Scores (DAS-CRP) (28 Joints) [DAS28] | -1.41 ± 1.45 | -0.72 ± 1.13 | -0.60 ± 0.98 |
Change from baseline in erythrocyte sedimentation rate (ESR) at Week 12
| mm/h | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Erythrocyte Sedimentation Rate (ESR) | -2.6 ± 19.3 | -0.3 ± 6.8 | -2.7 ± 16.6 |
Number of patients achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) \[DAS28-ESR\]remission, which is defined as DAS2-ESR \< 2.6
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Patients Achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) [DAS28-ESR] Remission | 2 | 0 | 0 |
The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (ESR), and patient's global assessment of disease activity (PtGA). DAS28-ESR = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.70 Ln \[ESR(mm/h)\] + 0.014 PtGA(VAS100mm) Score scale range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. change from baseline at weeks 12: the bigger negative score shows a bigger improvment
| mm/h | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Disease Activtiy Score (DAS)28-Erythrocyte Sedimentation Rate (ESR) | -1.43 ± 1.39 | -0.74 ± 1.11 | -0.59 ± 1.00 |
SDAI is a validated index of rheumatoid arthritis disease activity. The SDAI calculation is based on 28 tender and swollen joint counts, C-Reactive Protein (CRP), patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). SDAI score= tender28 + swollen28 + CRP + (PtGA/10) + (PrGA/10). A moderate activity is defined by a SDAI score \>11 to 26 included. A high activity is defined by a SDAI score \>26. Change from Baseline: the higher negative number shows a bigger improvment
| score on a scale | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Simplified Disease Activity Index Score (SDAI) | -20.21 ± 33.27 | -9.37 ± 14.44 | -7.58 ± 22.69 |
CDAI is a validated index of rheumatoid arthritis disease activity. The CDAI calculation is based on 28 tender and swollen joint counts, patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA). CDAI score= tender28 + swollen28 + (PtGA/10) + (PrGA/10). A moderate activity is defined by a CDAI score \>10 to 22 included. A high activity is defined by a CDAI score \>22. Change from Baseline: the higher negative number shows a bigger improvment
| score on a scale | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Clinical Disease Activity Index Score (CDAI) | -15.89 ± 13.29 | -9.99 ± 15.85 | -6.93 ± 10.13 |
Number of patients achieving a Low Disease Activity (LDA) which is defined as DAS28-ESR \<=3.2
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Patients Achieving Low Disease Activity (LDA) | 4 | 2 | 2 |
Number of patients achieving Simplified Disease Activity Score (SDAI) remission, which is considered achieved if the SDAI score ≤ 3.3
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Patients Achieving Simplified Disease Activity Score (SDAI) Remission | 1 | 0 | 0 |
Number of patients achieving Clinical Disease Activity (CDAI) remission, which is considered achieved if the CDAI score ≤ 2.8
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Patients Achieving Clinical Disease Activity (CDAI) Remission | 3 | 0 | 0 |
The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1
| Participants | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Number of Patients Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission | 1 | 0 | 0 |
Change from Baseline in Tender/painful joint count based on 28-joint assessment (TJC28) at Week 12 TJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is
| joints | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Tender/Painful Joint Count (TJC28) | -6.8 ± 6.4 | -4.1 ± 6.6 | -2.9 ± 3.8 |
Change from Baseline in Swollen joint count based on 28-joint assessment (SJC28) at Week 12 SJC28 score range from 0 to 28 Change from Baseline: the higher the negative number is, the better improvment is
| joints | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Swollen Joint Count (SJC) | -4.4 ± 4.2 | -3.2 ± 5.3 | -2.1 ± 4.2 |
Change from Baseline in Pain Visual Analog Scale (Pain-VAS) at week 12 The VAS range from 0 to 10 cm (the higher, the more painful) A bigger negative change from baseline shows a bigger improvment
| units on a scale | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Pain Visual Analog Scale | -2.63 ± 2.43 | -0.89 ± 1.97 | -0.78 ± 2.36 |
Change from Baseline in Patient Global Assessment of Disease (PtGA) . This is a patient's self assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: a bigger negative number shows a bigger improvment
| units on a scale | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Patient Global Assessment of Disease (PtGA) | -1.44 ± 1.92 | -0.89 ± 1.93 | -0.36 ± 2.16 |
Change from Baseline in Investigator global assessment of disease (PrGA): investigator's assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity The change from baseline: the higher negative number shows a better improvement
| units on a scale | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Investigator Global Assessment of Disease (PrGA) | -3.26 ± 2.7 | -1.89 ± 2.95 | -1.63 ± 2.38 |
Change from Baseline in Health Assessment questionnaire disability index (HAQ-DI) at Week 12 There are 8 sections in this questionnaire: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section, i.e. if one question is scored 1 and another 2, then the score for the section is 2. In addition, if an aide or device is used or if help is required from another individual, then the minimum score for that section is 2. The 8 scores of the 8 sections are summed and divided by the number of section answered. This gives a score range from 0 to 3 (the bigger the worst activity). The change from Baseline: the bigger negative number shows a bigger improvment
| units on a scale | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) | -0.4345 ± 0.6182 | -0.1053 ± 0.3443 | -0.1813 ± 0.4824 |
Collected over 15 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464 50mg + Methotrexate | 0/21 (0%) | 0/21 (0%) | 15/21 (71.4%) |
| ABX464 100mg + Methotrexate | 0/19 (0%) | 1/19 (5.3%) | 17/19 (89.5%) |
| Placebo + Methotrexate | 0/20 (0%) | 1/20 (5%) | 5/20 (25%) |
| Event | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/21 | 1/19 | 0/20 |
| Covid-19Infections and infestations | 0/21 | 0/19 | 1/20 |
| Event | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate |
|---|---|---|---|
| HeadacheNervous system disorders | 8/21 | 10/19 | 4/20 |
| nauseaGastrointestinal disorders | 3/21 | 9/19 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 4/21 | 7/19 | 1/20 |
| Abdominal pain upperGastrointestinal disorders | 5/21 | 4/19 | 1/20 |
| DyspepsiaGastrointestinal disorders | 1/21 | 3/19 | 0/20 |
| VomitingGastrointestinal disorders | 2/21 | 3/19 | 0/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/21 | 2/19 | 1/20 |
| abdominal painGastrointestinal disorders | 2/21 | 1/19 | 0/20 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/21 | 1/19 | 1/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/21 | 1/19 | 0/20 |
| Age, Continuous(years) | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Mean | 57.9 ± 11.4 | 54.4 ± 10.6 | 58.6 ± 11.0 | 57.0 ± 11.0 |
| Sex: Female, Male(Participants) | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Female | 15 | 11 | 11 | 37 |
| Male | 6 | 8 | 9 | 23 |
| Race and Ethnicity Not Collected(Participants) | ABX464 50mg + Methotrexate | ABX464 100mg + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Apr 2021, 21 months.
Results were first posted in Apr 2022, 11 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464